135 completed, 104 active not recruiting, 65 recruiting, 41 terminated. 250 Phase 2, 133 Phase 1, 43 Phase 3, 10 Early Phase 1, 6 Phase 4.
Follow olaparib: new trials by email Literature Review of olaparib trials Research Report on olaparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer Olaparib - Solid Tumor | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 30 | 2026-09-01 | 2025-12-11 |
| A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 180 | 2026-09-01 | 2026-07-23 |
| Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib - Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Immunomic Therapeutics, Inc. | 60 | 2026-07-14 | 2026-09-10 |
| PROLONG (PRostateOLaparibONcombinationGcc) Study Olaparib and Abiraterone Combination - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Not yet recruiting | AstraZeneca | 75 | 2026-06-30 | 2026-06-29 | |
| Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer DWZ2501 (Olaparib 150mg), DWC202510 (Olaparib 150mg) - Cancer, Ovarian Cancer | Phase 1 | Recruiting | Daewoong Pharmaceutical Co. LTD. | 40 | 2026-04-22 | 2026-05-08 |
| Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy Standard of care plus pembrolizumab, Standard of care (capecitabine or olaparib) - Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma | Phase 3 | Not yet recruiting | The Netherlands Cancer Institute | 1000 | 2026-04-01 | 2026-03-20 |
| Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) Temozolomide, Olaparib - Breast Cancer Triple Negative | Phase 2 | Not yet recruiting | AHS Cancer Control Alberta | 40 | 2026-04-01 | 2025-12-15 |
| QLS5132 Combination Therapy in Advanced Solid Tumors QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab - Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 626 | 2026-04-01 | 2026-03-06 |
| Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss MRTX1719, Olaparib - Advanced Cancer, Solid Tumor | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-02-12 | 2026-08-12 |
| Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer Iparomlimab and Tuvonralimab (QL1706)Injection, paclitaxel, carboplatin - Ovarian Cancers | Phase 2 | Not yet recruiting | Jiangsu Cancer Institute & Hospital | 50 | 2026-02-01 | 2026-02-12 |
| The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel Iparomlimab and tuvonralimab combined with olaparib and paclitaxel - Triple Negative Breast Cancer (TNBC) | Not applicable | Not yet recruiting | Harbin Medical University | 20 | 2025-12-30 | 2025-09-23 |
| Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer Cirtuvivint, Olaparib - Endometrioid Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 | Recruiting | University of Colorado, Denver | 50 | 2025-12-08 | 2026-07-24 |
| Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer Olaparib (300 mg BID), Pembrolizumab, 177Lu-PSMA-I&T - Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 1 | Withdrawn | Peter MacCallum Cancer Centre, Australia | 2025-11-01 | 2026-10-30 | |
| QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD) QL1706 + olaparib - Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 79 | 2025-08-30 | 2025-08-11 |
| A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies IMGN151, Carboplatin, Bevacizumab - Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer | Phase 2 | Recruiting | AbbVie | 377 | 2025-07-30 | 2026-10-01 |
| Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Imunon | 500 | 2025-07-09 | 2026-10-30 |
| Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer QL1706 Plus Olaparib - Triple-Negative Breast Cancer (TNBC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 46 | 2025-06-30 | 2025-06-05 |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Breast Neoplasms, Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 2400 | 2025-06-30 | 2026-10-13 |
| A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Olaparib 150 MG - Ovarian Cancer | Phase 1 | Recruiting | Boryung Pharmaceutical Co., Ltd | 24 | 2025-06-17 | 2025-07-16 |
Showing 20 of 418. Sign in to see all of them.
Ovarian Neoplasms (92) · Breast Neoplasms (69) · Prostatic Neoplasms (33) · Triple Negative Breast Neoplasms (33) · Neoplasms (26) · Fallopian Tube Neoplasms (25) · Neoplasm Metastasis (21) · Endometrial Neoplasms (18) · Pancreatic Neoplasms (18) · Small Cell Lung Carcinoma (13) · Carcinoma, Ovarian Epithelial (12) · Carcinoma, Non-Small-Cell Lung (10) · Fanconi Anemia, Complementation Group D1 (9) · Lung Neoplasms (9) · Recurrence (9)
AstraZeneca (72) · National Cancer Institute (NCI) (45) · Merck Sharp & Dohme LLC (16) · M.D. Anderson Cancer Center (13) · Memorial Sloan Kettering Cancer Center (9) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · The Netherlands Cancer Institute (7) · Dana-Farber Cancer Institute (6) · Gustave Roussy, Cancer Campus, Grand Paris (6) · University Health Network, Toronto (5) · Institute of Cancer Research, United Kingdom (4) · OHSU Knight Cancer Institute (4) · University of Colorado, Denver (4) · University of Washington (4) · ARCAGY/ GINECO GROUP (3)
United States (217) · United Kingdom (80) · Spain (71) · Canada (65) · France (65) · South Korea (53) · Italy (51) · Germany (44) · Australia (41) · China (40) · Japan (40) · Netherlands (36) · Belgium (34) · Poland (31) · Israel (29)
Jane Robertson, BSc, MBCHB, MD (12) · Amit Oza, M.D. (3) · James Carmichael, BSc MBChB MD FRCP (3) · Joyce F Liu (3) · Patricia M LoRusso (3) · Shannon N Westin (3) · Xiaoxiang Chen, MD,PhD (3) · Andrew Tutt, PhD MRCP FRCR (2) · Anitra Fielding (2) · Filipa Lynce, MD (2) · Fred Saad, MD (2) · Gabe Sonke, MD, PhD (2) · James Carmichael, BSc, MBChB, MD, FRCP (2)
PMID 35170751, PMID 26961146, PMID 39695768, PMID 23922302, PMID 34904813, PMID 37185961, PMID 32379297, PMID 31500595, PMID 38885312, PMID 19238149, PMID 22248721, PMID 32073956, PMID 33927108, PMID 40525978, PMID 40607251, PMID 42686334, PMID 42820295, PMID 19553641, PMID 20609467, PMID 20609468, PMID 21796368, PMID 21862407, PMID 22145984, PMID 22198468, PMID 22452356, PMID 22623692, PMID 22649152, PMID 23524863, PMID 23810467, PMID 24063698, PMID 24882434, PMID 25025963, PMID 25218906, PMID 25374341, PMID 25481791, PMID 25554012, PMID 25573533, PMID 26242220, PMID 26410619, PMID 26510020, PMID 26723501, PMID 27062051, PMID 27075016, PMID 27169564, PMID 27323902, PMID 27324108, PMID 27406346, PMID 27406347, PMID 27617661, PMID 27824811
2018 (14), 2023 (14), 2017 (11), 2016 (10), UM1CA186689 (9), 2019 (8), U10CA180868 (8), 2015 (7), UM1CA186709 (7), 2014 (5), 2008 (3), U10CA180821 (3), UM1CA186644 (3), UM1CA186686 (3), UM1CA186688 (3)